Merus Labs is a biopharma company focused on acquiring established products to optimize the value of underdeveloped pharmaceutical assets.
Merus Labs – targeting underdeveloped biopharma assets
Merus Labs’ strategy is driven by an opportunistic but highly disciplined approach to source product acquisition candidates, in order to source established pharmaceutical products across broad therapeutic categories. Merus Labs targets underdeveloped biopharma assets and optimize their return through cost efficiencies, price opportunities and promotional efforts which drive volume growth. Merus Labs is mainly focused on the European and North American markets. For instance, Merus Labs develops Sintrom (acenocoumarol), an anticoagulant treating and preventing thromboembolic diseases. Sintrom works by partially blocking the reuse of vitamin K in the liver. Sintrom is primarily used to prevent and treat blood clots in veins and lungs as well as atrial fibrillation. Moreover, Merus Labs also develops Enablex (darifenacin), also called Emselex, used to treat overactive bladder syndrome by blocking the nerve signals causing involuntary contraction of the bladder. Furthermore, Merus Labs develops Vancocin (vancomycin), capsules treating infections caused by bacteria such as C.difficile in the gastrointestinal tract.
Merus Labs is a biopharma company based in Canada. Management Team is composed by Ulrich Schoeberl, Andrew Patient, Bob McLay, Geoff Morrow, Michael Cloutier, Barry Fishman (CEO), Robert Pollock, Tim Sorenson, David Guebert and Theresa Firestone.
More about MerusLabs : www.meruslabs.com